ABSTRACT
It is rare to have a trial that has 100% complete data, and how the biostatistician deals with the missing data varies widely (Altman and Bland 2007). Given the many possibilities for dealing with missing data, there are many possibilities of cost-effectiveness results from the analysis of a pivotal trial or literature-based cost-effectiveness model. It is then left to the experienced reviewer who relies on his own judgement on whether the extent of missing data has the potential to impact the cost-effectiveness conclusion.
